Patents by Inventor Songwen LIN

Songwen LIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
    Publication number: 20230110550
    Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.
    Type: Application
    Filed: September 13, 2022
    Publication date: April 13, 2023
    Inventors: Heng XU, Xiaoguang Chen, Songwen LIN, Ming JI, Jing JIN, Deyu WU, Chunyang Wang, Yuanhao LV
  • Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
    Publication number: 20230113478
    Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.
    Type: Application
    Filed: September 13, 2022
    Publication date: April 13, 2023
    Inventors: Heng XU, Xiaoguang Chen, Songwen LIN, Ming JI, Jing JIN, Deyu WU, Chunyang Wang, Yuanhao LV
  • BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF
    Publication number: 20230099912
    Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.
    Type: Application
    Filed: October 27, 2022
    Publication date: March 30, 2023
    Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Heng XU, Xiaoguang CHEN, Songwen LIN, Ming JI, Nina XUE, Deyu WU, Jing JIN
  • Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof
    Patent number: 11534443
    Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: December 27, 2022
    Assignee: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Heng Xu, Xiaoguang Chen, Songwen Lin, Ming Ji, Jing Jin, Deyu Wu, Chunyang Wang, Yuanhao Lv
  • Benzamide compound and preparation method, use, and pharmaceutical composition thereof
    Patent number: 11518744
    Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: December 6, 2022
    Assignee: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Heng Xu, Xiaoguang Chen, Songwen Lin, Ming Ji, Nina Xue, Deyu Wu, Jing Jin
  • Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
    Publication number: 20210128559
    Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.
    Type: Application
    Filed: December 26, 2017
    Publication date: May 6, 2021
    Inventors: Heng XU, Xiaoguang CHEN, Songwen LIN, Ming JI, Jing JIN, Deyu WU, Chunyang WANG, Yuanhao LV
  • BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF
    Publication number: 20210047270
    Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.
    Type: Application
    Filed: January 30, 2019
    Publication date: February 18, 2021
    Inventors: Heng XU, Xiaoguang CHEN, Songwen LIN, Ming JI, Nina XUE, Deyu WU, Jing JIN
  • Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
    Patent number: 9902709
    Abstract: The present invention provides a polysubstituted pyridine compound of Formula I, a preparation method, a use and a pharmaceutical composition thereof. The polysubstituted pyridine compound of Formula I according to the present invention has an excellent anti-tumor effect, can inhibit various cell kinases simultaneously, has significantly excellent pharmacokinetic characteristics, and is very suitable for oral and intravenous administration. The pharmaceutical composition according to the present invention can be useful for treating tumors and cancers.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: February 27, 2018
    Assignees: PEKING UNIVERSITY FOUNDER GROUP CO., LTD., PKUCARE PHARMACEUTICAL R & D CENTER, PKU HEALTHCARE INDUSTRY GROUP CO., LTD.
    Inventors: Chongqin Yi, Heng Xu, Jing Tao, Songwen Lin, Fangbin Han
  • POLYSUBSTITUTED PYRIDINE COMPOUND, PREPARATION METHOD, USE AND PHARMACEUTICAL COMPOSITION
    Publication number: 20170029404
    Abstract: The present invention provides a polysubstituted pyridine compound of Formula I, a preparation method, a use and a pharmaceutical composition thereof. The polysubstituted pyridine compound of Formula I according to the present invention has an excellent anti-tumor effect, can inhibit various cell kinases simultaneously, has significantly excellent pharmacokinetic characteristics, and is very suitable for oral and intravenous administration. The pharmaceutical composition according to the present invention can be useful for treating tumors and cancers.
    Type: Application
    Filed: December 30, 2014
    Publication date: February 2, 2017
    Inventors: Chongqin YI, Heng XU, Jing TAO, Songwen LIN, Fangbin HAN